392 related articles for article (PubMed ID: 25667438)
1. Mechanisms and clinical significance of histone deacetylase inhibitors: epigenetic glioblastoma therapy.
Lee P; Murphy B; Miller R; Menon V; Banik NL; Giglio P; Lindhorst SM; Varma AK; Vandergrift WA; Patel SJ; Das A
Anticancer Res; 2015 Feb; 35(2):615-25. PubMed ID: 25667438
[TBL] [Abstract][Full Text] [Related]
2. Histone Deacetylase (HDAC) Inhibitors: Current Evidence for Therapeutic Activities in Pancreatic Cancer.
Damaskos C; Garmpis N; Karatzas T; Nikolidakis L; Kostakis ID; Garmpi A; Karamaroudis S; Boutsikos G; Damaskou Z; Kostakis A; Kouraklis G
Anticancer Res; 2015 Jun; 35(6):3129-35. PubMed ID: 26026072
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors in glioblastoma: pre-clinical and clinical experience.
Bezecny P
Med Oncol; 2014 Jun; 31(6):985. PubMed ID: 24838514
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
5. The application of histone deacetylases inhibitors in glioblastoma.
Chen R; Zhang M; Zhou Y; Guo W; Yi M; Zhang Z; Ding Y; Wang Y
J Exp Clin Cancer Res; 2020 Jul; 39(1):138. PubMed ID: 32682428
[TBL] [Abstract][Full Text] [Related]
6. Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft.
Tarasenko N; Nudelman A; Rozic G; Cutts SM; Rephaeli A
Invest New Drugs; 2017 Aug; 35(4):412-426. PubMed ID: 28315153
[TBL] [Abstract][Full Text] [Related]
7. Advances in histone deacetylase inhibitors in targeting glioblastoma stem cells.
Reddy RG; Bhat UA; Chakravarty S; Kumar A
Cancer Chemother Pharmacol; 2020 Aug; 86(2):165-179. PubMed ID: 32638092
[TBL] [Abstract][Full Text] [Related]
8. [Epigenetic mechanisms and alcohol use disorders: a potential therapeutic target].
Legastelois R; Jeanblanc J; Vilpoux C; Bourguet E; Naassila M
Biol Aujourdhui; 2017; 211(1):83-91. PubMed ID: 28682229
[TBL] [Abstract][Full Text] [Related]
9. Advances in epigenetic glioblastoma therapy.
Lee DH; Ryu HW; Won HR; Kwon SH
Oncotarget; 2017 Mar; 8(11):18577-18589. PubMed ID: 28099914
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors in the treatment of hematological malignancies.
Petrella A; Fontanella B; Carratù A; Bizzarro V; Rodriquez M; Parente L
Mini Rev Med Chem; 2011 Jun; 11(6):519-27. PubMed ID: 21561404
[TBL] [Abstract][Full Text] [Related]
11. Targeting miRNAs by histone deacetylase inhibitors (HDACi): Rationalizing epigenetics-based therapies for breast cancer.
Ediriweera MK; Cho SK
Pharmacol Ther; 2020 Feb; 206():107437. PubMed ID: 31715287
[TBL] [Abstract][Full Text] [Related]
12. Histone Deacetylase Inhibitors and Diabetic Kidney Disease.
Hadden MJ; Advani A
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30189630
[TBL] [Abstract][Full Text] [Related]
13. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
Hanikoglu A; Hanikoglu F; Ozben T
Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
[TBL] [Abstract][Full Text] [Related]
14. LBH589 Inhibits Glioblastoma Growth and Angiogenesis Through Suppression of HIF-1α Expression.
Yao ZG; Li WH; Hua F; Cheng HX; Zhao MQ; Sun XC; Qin YJ; Li JM
J Neuropathol Exp Neurol; 2017 Dec; 76(12):1000-1007. PubMed ID: 29136455
[TBL] [Abstract][Full Text] [Related]
15. Histone Deacetylase Inhibitors as Anticancer Drugs.
Eckschlager T; Plch J; Stiborova M; Hrabeta J
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
[TBL] [Abstract][Full Text] [Related]
16. Emerging role of histone deacetylase inhibitors as anti-breast-cancer agents.
Ediriweera MK; Tennekoon KH; Samarakoon SR
Drug Discov Today; 2019 Mar; 24(3):685-702. PubMed ID: 30776482
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?
Harrison IF; Dexter DT
Pharmacol Ther; 2013 Oct; 140(1):34-52. PubMed ID: 23711791
[TBL] [Abstract][Full Text] [Related]
18. Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer.
Damaskos C; Garmpis N; Valsami S; Kontos M; Spartalis E; Kalampokas T; Kalampokas E; Athanasiou A; Moris D; Daskalopoulou A; Davakis S; Tsourouflis G; Kontzoglou K; Perrea D; Nikiteas N; Dimitroulis D
Anticancer Res; 2017 Jan; 37(1):35-46. PubMed ID: 28011471
[TBL] [Abstract][Full Text] [Related]
19. Application of the histone deacetylase inhibitors for the treatment of endometriosis: histone modifications as pathogenesis and novel therapeutic target.
Kawano Y; Nasu K; Li H; Tsuno A; Abe W; Takai N; Narahara H
Hum Reprod; 2011 Sep; 26(9):2486-98. PubMed ID: 21715447
[TBL] [Abstract][Full Text] [Related]
20. The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat.
Zagni C; Floresta G; Monciino G; Rescifina A
Med Res Rev; 2017 Nov; 37(6):1373-1428. PubMed ID: 28181261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
